1. J. D. Watson, F. H. Crick, Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 171, 737-738, 1953.
2. F. Sanger, S. Nicklen, A. R. Coulson, DNA sequencing with chain- terminating inhibitors. Proc Natl Acad Sci U S A 74, 5463-5467, 1977.
3. A. M. Maxam, W. Gilbert, A new method for sequencing DNA. Proc Natl Acad Sci U S A 74, 560-564, 1977.
4. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550, 2014.
5. E. S. Lander, L. M. Linton, B. Birren, C. Nusbaum, M. C. Zody, J. Baldwin, K. Devon, K. Dewar, M. Doyle, W. FitzHugh, R. Funke, D. Gage, K. Harris, A. Heaford, J. Howland, L. Kann, J. Lehoczky, R. LeVine, P. McEwan, K. McKernan, J. Meldrim, J. P. Mesirov, C. Miranda, W. Morris, J. Naylor, C. Raymond, M. Rosetti, R. Santos, A. Sheridan, C. Sougnez, Y. Stange-Thomann, N. Stojanovic, A. Subramanian, D. Wyman, J. Rogers, J. Sulston, R. Ainscough, S. Beck, D. Bentley, J. Burton, C. Clee, N. Carter, A. Coulson, R. Deadman, P. Deloukas, A. Dunham, I. Dunham, R. Durbin, L. French, D. Grafham, S. Gregory, T. Hubbard, S. Humphray, A. Hunt, M. Jones, C. Lloyd, A. McMurray, L. Matthews, S. Mercer, S. Milne, J. C. Mullikin, A. Mungall, R. Plumb, M. Ross, R. Shownkeen, S. Sims, R. H. Waterston, R. K. Wilson, L. W. Hillier, J. D. McPherson, M. A. Marra, E. R. Mardis, L. A. Fulton, A. T. Chinwalla, K. H. Pepin, W. R. Gish, S. L. Chissoe, M. C. Wendl, K. D. Delehaunty, T. L. Miner, A. Delehaunty, J. B. Kramer, L. L. Cook, R. S. Fulton, D. L. Johnson, P. J. Minx, S. W. Clifton, T. Hawkins, E. Branscomb, P. Predki, P. Richardson, S. Wenning, T. Slezak, N. Doggett, J. F. Cheng, A. Olsen, S. Lucas, C. Elkin, E. Uberbacher, M. Frazier, R. A. Gibbs, D. M. Muzny, S. E. Scherer, J. B. Bouck, E. J. Sodergren, K. C. Worley, C. M. Rives, J. H. Gorrell, M. L. Metzker, S. L. Naylor, R. S. Kucherlapati, D. L. Nelson, G. M. Weinstock, Y. Sakaki, A. Fujiyama, M. Hattori, T. Yada, A. Toyoda, T. Itoh, C. Kawagoe, H. Watanabe, Y. Totoki, T. Taylor, J. Weissenbach, R. Heilig, W. Saurin, F. Artiguenave, P. Brottier, T. Bruls, E. Pelletier, C. Robert, P. Wincker, D. R. Smith, L. Doucette-Stamm, M. Rubenfield, K. Weinstock, H. M. Lee, J. Dubois, A. Rosenthal, M. Platzer, G. Nyakatura, S. Taudien, A. Rump, H. Yang, J. Yu, J. Wang, G. Huang, J. Gu, L. Hood, L. Rowen, A. Madan, S. Qin, R. W. Davis, N. A. Federspiel, A. P. Abola, M. J. Proctor, R. M. Myers, J. Schmutz, M. Dickson, J. Grimwood, D. R. Cox, M. V. Olson, R. Kaul, C. Raymond, N. Shimizu, K. Kawasaki, S. Minoshima, G. A. Evans, M. Athanasiou, R. Schultz, B. A. Roe, F. Chen, H. Pan, J. Ramser, H. Lehrach, R. Reinhardt, W. R. McCombie, M. de la Bastide, N. Dedhia, H. Blocker, K. Hornischer, G. Nordsiek, R. Agarwala, L. Aravind, J. A. Bailey, A. Bateman, S. Batzoglou, E. Birney, P. Bork, D. G. Brown, C. B. Burge, L. Cerutti, H. C. Chen, D. Church, M. Clamp, R. R. Copley, T. Doerks, S. R. Eddy, E. E. Eichler, T. S. Furey, J. Galagan, J. G. Gilbert, C. Harmon, Y. Hayashizaki, D. Haussler, H. Hermjakob, K. Hokamp, W. Jang, L. S. Johnson, T. A. Jones, S. Kasif, A. Kaspryzk, S. Kennedy, W. J. Kent, P. Kitts, E. V. Koonin, I. Korf, D. Kulp, D. Lancet, T. M. Lowe, A. McLysaght, T. Mikkelsen, J. V. Moran, N. Mulder, V. J. Pollara, C. P. Ponting, G. Schuler, J. Schultz, G. Slater, A. F. Smit, E. Stupka, J. Szustakowki, D. Thierry-Mieg, J. Thierry-Mieg, L. Wagner, J. Wallis, R. Wheeler, A. Williams, Y. I. Wolf, K. H. Wolfe, S. P. Yang, R. F. Yeh, F. Collins, M. S. Guyer, J. Peterson, A. Felsenfeld, K. A. Wetterstrand, A. Patrinos, M. J. Morgan, P. de Jong, J. J. Catanese, K. Osoegawa, H. Shizuya, S. Choi, Y. J. Chen, J. Szustakowki, Initial sequencing and analysis of the human genome. Nature 409, 860-921, 2001.
6. A. Zehir, R. Benayed, R. H. Shah, A. Syed, S. Middha, H. R. Kim, P. Srinivasan, J. Gao, D. Chakravarty, S. M. Devlin, M. D. Hellmann, D. A. Barron, A. M. Schram, M. Hameed, S. Dogan, D. S. Ross, J. F. Hechtman, D. F. DeLair, J. Yao, D. L. Mandelker, D. T. Cheng, R. Chandramohan, A. S. Mohanty, R. N. Ptashkin, G. Jayakumaran, M. Prasad, M. H. Syed, A. B. Rema, Z. Y. Liu, K. Nafa, L. Borsu, J. Sadowska, J. Casanova, R. Bacares, I. J. Kiecka, A. Razumova, J. B. Son, L. Stewart, T. Baldi, K. A. Mullaney, H. Al-Ahmadie, E. Vakiani, A. A. Abeshouse, A. V. Penson, P. Jonsson, N. Camacho, M. T. Chang, H. H. Won, B. E. Gross, R. Kundra, Z. J. Heins, H. W. Chen, S. Phillips, H. Zhang, J. Wang, A. Ochoa, J. Wills, M. Eubank, S. B. Thomas, S. M. Gardos, D. N. Reales, J. Galle, R. Durany, R. Cambria, W. Abida, A. Cercek, D. R. Feldman, M. M. Gounder, A. A. Hakimi, J. J. Harding, G. Iyer, Y. Y. Janjigian, E. J. Jordan, C. M. Kelly, M. A. Lowery, L. G. T. Morris, A. M. Omuro, N. Raj, P. Razavi, A. N. Shoushtari, N. Shukla, T. E. Soumerai, A. M. Varghese, R. Yaeger, J. Coleman, B. Bochner, G. J. Riely, L. B. Saltz, H. I. Scher, P. J. Sabbatini, M. E. Robson, D. S. Klimstra, B. S. Taylor, J. Baselga, N. Schultz, D. M. Hyman, M. E. Arcila, D. B. Solit, M. Ladanyi, M. F. Berger, Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23, 703-713, 2017.
7. S. Kohsaka, M. Nagano, T. Ueno, Y. Suehara, T. Hayashi, N. Shimada, K. Takahashi, K. Suzuki, K. Takamochi, F. Takahashi, H. Mano, A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. Sci Transl Med 9, eaan6566, 2017.
8. R. Tamaskovic, M. Schwill, G. Nagy-Davidescu, C. Jost, D. C. Schaefer, W. P. Verdurmen, J. V. Schaefer, A. Honegger, A. Pluckthun, Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk. Nat Commun 7, 11672, 2016.
9. D. J. Slamon, W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich, et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (New York, N.Y.) 244, 707-712, 1989.
10. S. J. McKenzie, K. A. DeSombre, B. S. Bast, D. R. Hollis, R. S. Whitaker, A. Berchuck, C. M. Boyer, R. C. Bast, Jr., Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer 71, 3942-3946, 1993.
11. M. F. Press, M. C. Pike, G. Hung, J. Y. Zhou, Y. Ma, J. George, J. Dietz-Band, W. James, D. J. Slamon, J. G. Batsakis, et al., Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54, 5675-5682, 1994.
12. D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, L. Norton, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine 344, 783-792, 2001.
13. C. E. Geyer, J. Forster, D. Lindquist, S. Chan, C. G. Romieu, T. Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, D. Skarlos, M. Campone, N. Davidson, M. Berger, C. Oliva, S. D. Rubin, S. Stein, D. Cameron, Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine 355, 2733-2743, 2006.
14. J. Baselga, J. Cortes, S. B. Kim, S. A. Im, R. Hegg, Y. H. Im, L. Roman, J. L. Pedrini, T. Pienkowski, A. Knott, E. Clark, M. C. Benyunes, G. Ross, S. M. Swain, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England journal of medicine 366, 109-119, 2012.
15. A. Goldhirsch, R. D. Gelber, M. J. Piccart-Gebhart, E. de Azambuja, M. Procter, T. M. Suter, C. Jackisch, D. Cameron, H. A. Weber, D. Heinzmann, L. D. Lago, E. McFadden, M. Dowsett, M. Untch, L. Gianni, R. Bell, C.-H. Köhne, A. Vindevoghel, M. Andersson, A. M. Brunt, D. Otero-Reyes, S. Song, I. Smith, B. Leyland-Jones, J. Baselga, 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open- label, randomised controlled trial. The Lancet 382, 1021-1028, 2013.
16. D. Cameron, M. Casey, C. Oliva, B. Newstat, B. Imwalle, C. E. Geyer, Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15, 924-934, 2010.
17. Hickinson DM, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, Beck S, Marshall G, Davenport S, Callis R, Mills E, Grosios K, Smith P, Barlaam B, Wilkinson RW, Ogilvie D, AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clinical Cancer Research 16, 1159-1169, 2010.
18. P. Stephens, C. Hunter, G. Bignell, S. Edkins, H. Davies, J. Teague, C. Stevens, S. O'Meara, R. Smith, A. Parker, A. Barthorpe, M. Blow, L. Brackenbury, A. Butler, O. Clarke, J. Cole, E. Dicks, A. Dike, A. Drozd, K. Edwards, S. Forbes, R. Foster, K. Gray, C. Greenman, K. Halliday, K. Hills, V. Kosmidou, R. Lugg, A. Menzies, J. Perry, R. Petty, K. Raine, L. Ratford, R. Shepherd, A. Small, Y. Stephens, C. Tofts, J. Varian, S. West, S. Widaa, A. Yates, F. Brasseur, C. S. Cooper, A. M. Flanagan, M. Knowles, S. Y. Leung, D. N. Louis, L. H. Looijenga, B. Malkowicz, M. A. Pierotti, B. Teh, G. Chenevix- Trench, B. L. Weber, S. T. Yuen, G. Harris, P. Goldstraw, A. G. Nicholson, P. A. Futreal, R. Wooster, M. R. Stratton, Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526, 2004.
19. R. Bose, S. M. Kavuri, A. C. Searleman, W. Shen, D. Shen, D. C. Koboldt, J. Monsey, N. Goel, A. B. Aronson, S. Li, C. X. Ma, L. Ding, E. R. Mardis, M. J. Ellis, Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3, 224-237, 2013.
20. J. Mazieres, S. Peters, B. Lepage, A. B. Cortot, F. Barlesi, M. Beau-Faller, B. Besse, H. Blons, A. Mansuet-Lupo, T. Urban, D. Moro-Sibilot, E. Dansin, C. Chouaid, M. Wislez, J. Diebold, E. Felip, I. Rouquette, J. D. Milia, O. Gautschi, Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 31, 1997-2003, 2013.
21. J. W. Lee, Y. H. Soung, S. H. Seo, S. Y. Kim, C. H. Park, Y. P. Wang, K. Park, S. W. Nam, W. S. Park, S. H. Kim, J. Y. Lee, N. J. Yoo, S. H. Lee, Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 12, 57-61, 2006.
22. T. Bekaii-Saab, N. Williams, C. Plass, M. V. Calero, C. Eng, A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC cancer 6, 278, 2006.
23. N. Cancer Genome Atlas Research, Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615, 2011.
24. G. Guo, X. Sun, C. Chen, S. Wu, P. Huang, Z. Li, M. Dean, Y. Huang, W. Jia, Q. Zhou, A. Tang, Z. Yang, X. Li, P. Song, X. Zhao, R. Ye, S. Zhang, Z. Lin, M. Qi, S. Wan, L. Xie, F. Fan, M. L. Nickerson, X. Zou, X. Hu, L. Xing, Z. Lv, H. Mei, S. Gao, C. Liang, Z. Gao, J. Lu, Y. Yu, C. Liu, L. Li, X. Fang, Z. Jiang, J. Yang, C. Li, X. Zhao, J. Chen, F. Zhang, Y. Lai, Z. Lin, F. Zhou, H. Chen, H. C. Chan, S. Tsang, D. Theodorescu, Y. Li, X. Zhang, J. Wang, H. Yang, Y. Gui, J. Wang, Z. Cai, Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 45, 1459-1463, 2013.
25. H. Greulich, B. Kaplan, P. Mertins, T. H. Chen, K. E. Tanaka, C. H. Yun, X. Zhang, S. H. Lee, J. Cho, L. Ambrogio, R. Liao, M. Imielinski, S. Banerji, A. H. Berger, M. S. Lawrence, J. Zhang, N. H. Pho, S. R. Walker, W. Winckler, G. Getz, D. Frank, W. C. Hahn, M. J. Eck, D. R. Mani, J. D. Jaffe, S. A. Carr, K. K. Wong, M. Meyerson, Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A 109, 14476-14481, 2012.
26. S. M. Kavuri, N. Jain, F. Galimi, F. Cottino, S. M. Leto, G. Migliardi, A. C. Searleman, W. Shen, J. Monsey, L. Trusolino, S. A. Jacobs, A. Bertotti, R. Bose, HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov 5, 832- 841, 2015.
27. S. Breslin, M. C. Lowry, L. O'Driscoll, Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4. Br J Cancer 116, 620-625, 2017.
28. J. De Greve, E. Teugels, C. Geers, L. Decoster, D. Galdermans, J. De Mey, H. Everaert, I. Umelo, P. In't Veld, D. Schallier, Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung cancer (Amsterdam, Netherlands) 76, 123-127, 2012.
29. L. Gandhi, R. Bahleda, S. M. Tolaney, E. L. Kwak, J. M. Cleary, S. S. Pandya, A. Hollebecque, R. Abbas, R. Ananthakrishnan, A. Berkenblit, M. Krygowski, Y. Liang, K. W. Turnbull, G. I. Shapiro, J. C. Soria, Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 32, 68-75, 2014.
30. M. G. Kris, D. R. Camidge, G. Giaccone, T. Hida, B. T. Li, J. O'Connell, I. Taylor, H. Zhang, M. E. Arcila, Z. Goldberg, P. A. Janne, Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol 26, 1421-1427, 2015.
31. D. M. Hyman, S. A. Piha-Paul, H. Won, J. Rodon, C. Saura, G. I. Shapiro, D. Juric, D. I. Quinn, V. Moreno, B. Doger, I. A. Mayer, V. Boni, E. Calvo, S. Loi, A. C. Lockhart, J. P. Erinjeri, M. Scaltriti, G. A. Ulaner, J. Patel, J. Tang, H. Beer, S. D. Selcuklu, A. J. Hanrahan, N. Bouvier, M. Melcer, R. Murali, A. M. Schram, L. M. Smyth, K. Jhaveri, B. T. Li, A. Drilon, J. J. Harding, G. Iyer, B. S. Taylor, M. F. Berger, R. E. Cutler, Jr., F. Xu, A. Butturini, L. D. Eli, G. Mann, C. Farrell, A. S. Lalani, R. P. Bryce, C. L. Arteaga, F. Meric- Bernstam, J. Baselga, D. B. Solit, HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554, 189- 194, 2018.
32. S. Liu, S. Li, J. Hai, X. Wang, T. Chen, M. M. Quinn, P. Gao, Y. Zhang, H. Ji, D. A. E. Cross, K. K. Wong, Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib. Clin Cancer Res, 2018.
33. W. J. Zuo, Y. Z. Jiang, Y. J. Wang, X. E. Xu, X. Hu, G. Y. Liu, J. Wu, G. H. Di, K. D. Yu, Z. M. Shao, Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer. Clin Cancer Res 22, 4859-4869, 2016.
34. A. B. Hanker, M. R. Brewer, J. H. Sheehan, J. P. Koch, G. R. Sliwoski, R. Nagy, R. Lanman, M. F. Berger, D. M. Hyman, D. B. Solit, J. He, V. Miller, R. E. Cutler, Jr., A. S. Lalani, D. Cross, C. M. Lovly, J. Meiler, C. L. Arteaga, An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discov 7, 575-585, 2017.
35. T. Akagi, K. Sasai, H. Hanafusa, Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation. Proc Natl Acad Sci U S A 100, 13567-13572, 2003.
36. B. Page, M. Page, C. Noel, A new fluorometric assay for cytotoxicity measurements in-vitro. Int J Oncol 3, 473-476, 1993.
37. M. T. Chang, T. S. Bhattarai, A. M. Schram, C. M. Bielski, M. T. A. Donoghue, P. Jonsson, D. Chakravarty, S. Phillips, C. Kandoth, A. Penson, A. Gorelick, T. Shamu, S. Patel, C. Harris, J. Gao, S. O. Sumer, R. Kundra, P. Razavi, B. T. Li, D. N. Reales, N. D. Socci, G. Jayakumaran, A. Zehir, R. Benayed, M. E. Arcila, S. Chandarlapaty, M. Ladanyi, N. Schultz, J. Baselga, M. F. Berger, N. Rosen, D. B. Solit, D. M. Hyman, B. S. Taylor, Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discov 8, 174-183, 2018.
38. R. K. Kancha, N. von Bubnoff, N. Bartosch, C. Peschel, R. A. Engh, J. Duyster, Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS One 6, e26760, 2011.
39. T. Trowe, S. Boukouvala, K. Calkins, R. E. Cutler, Jr., R. Fong, R. Funke, S. B. Gendreau, Y. D. Kim, N. Miller, J. R. Woolfrey, V. Vysotskaia, J. P. Yang, M. E. Gerritsen, D. J. Matthews, P. Lamb, T. S. Heuer, EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res 14, 2465-2475, 2008.
40. K. Uchibori, N. Inase, M. Araki, M. Kamada, S. Sato, Y. Okuno, N. Fujita, R. Katayama, Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non- small-cell lung cancer. Nat Commun 8, 14768, 2017.
41. T. Kosaka, J. Tanizaki, R. M. Paranal, H. Endoh, C. Lydon, M. Capelletti, C. E. Repellin, J. Choi, A. Ogino, A. Calles, D. Ercan, A. J. Redig, M. Bahcall, G. R. Oxnard, M. J. Eck, P. A. Janne, Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Res 77, 2712-2721, 2017.
42. D. Planchard, K. H. Brown, D. W. Kim, S. W. Kim, Y. Ohe, E. Felip, P. Leese, M. Cantarini, K. Vishwanathan, P. A. Janne, M. Ranson, P. A. Dickinson, Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer chemotherapy and pharmacology 77, 767-776, 2016.
43. J. W. Yates, S. Ashton, D. Cross, M. J. Mellor, S. J. Powell, P. Ballard, Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104. Molecular cancer therapeutics 15, 2378-2387, 2016.
44. S. Wind, D. Schnell, T. Ebner, M. Freiwald, P. Stopfer, Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Clinical pharmacokinetics 56, 235-250, 2017.
45. R. W. Sparidans, S. van Hoppe, J. J. Rood, A. H. Schinkel, J. H. Schellens, J. H. Beijnen, Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 1012-1013, 118-123, 2016.
46. E. Y. Kim, E. N. Cho, H. S. Park, J. Y. Hong, S. Lim, J. P. Youn, S. Y. Hwang, Y. S. Chang, Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther 17, 237-245, 2016.
47. S. Kobayashi, H. M. Canepa, A. S. Bailey, S. Nakayama, N. Yamaguchi, M. A. Goldstein, M. S. Huberman, D. B. Costa, Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8, 45-51, 2013.
48. D. R. Boulbes, S. T. Arold, G. B. Chauhan, K. V. Blachno, N. Deng, W. C. Chang, Q. Jin, T. H. Huang, J. M. Hsu, S. W. Brady, C. Bartholomeusz, J. E. Ladbury, S. Stone, D. Yu, M. C. Hung, F. J. Esteva, HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Molecular oncology 9, 586-600, 2015.
49. R. Mishra, A. B. Hanker, J. T. Garrett, Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget 8, 114371-114392, 2017.
50. J. D. Hainsworth, F. Meric-Bernstam, C. Swanton, H. Hurwitz, D. R. Spigel, C. Sweeney, H. Burris, R. Bose, B. Yoo, A. Stein, M. Beattie, R. Kurzrock, Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol 36, 536-542, 2018.
51. D. J. Zabransky, C. L. Yankaskas, R. L. Cochran, H. Y. Wong, S. Croessmann, D. Chu, S. M. Kavuri, M. Red Brewer, D. M. Rosen, W. B. Dalton, A. Cimino-Mathews, K. Cravero, B. Button, K. Kyker- Snowman, J. Cidado, B. Erlanger, H. A. Parsons, K. M. Manto, R. Bose, J. Lauring, C. L. Arteaga, K. Konstantopoulos, B. H. Park, HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A 112, E6205- 6214, 2015.
52. X. Xu, C. De Angelis, K. A. Burke, A. Nardone, H. Hu, L. Qin, J. Veeraraghavan, V. Sethunath, L. M. Heiser, N. Wang, C. K. Y. Ng, E. S. Chen, A. Renwick, T. Wang, S. Nanda, M. Shea, T. Mitchell, M. Rajendran, I. Waters, D. J. Zabransky, K. L. Scott, C. Gutierrez, C. Nagi, F. C. Geyer, G. C. Chamness, B. H. Park, C. A. Shaw, S. G. Hilsenbeck, M. F. Rimawi, J. W. Gray, B. Weigelt, J. S. Reis-Filho, C. K. Osborne, R. Schiff, HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2(+) Breast Cancer. Clin Cancer Res 23, 5123-5134, 2017.
53. C. X. Ma, R. Bose, F. Gao, R. A. Freedman, M. L. Telli, G. Kimmick, E. Winer, M. Naughton, M. P. Goetz, C. Russell, D. Tripathy, M. Cobleigh, A. Forero, T. J. Pluard, C. Anders, P. A. Niravath, S. Thomas, J. Anderson, C. Bumb, K. C. Banks, R. B. Lanman, R. Bryce, A. S. Lalani, J. Pfeifer, D. F. Hayes, M. Pegram, K. Blackwell, P. L. Bedard, H. Al-Kateb, M. J. C. Ellis, Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clin Cancer Res 23, 5687-5695, 2017.
54. S. S. Ramalingam, J. C. Yang, C. K. Lee, T. Kurata, D. W. Kim, T. John, N. Nogami, Y. Ohe, H. Mann, Y. Rukazenkov, S. Ghiorghiu, D. Stetson, A. Markovets, J. C. Barrett, K. S. Thress, P. A. Janne, Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 36, 841-849, 2018.
55. E. F. Smit, S. Peters, R. Dziadziuszko, U. Dafni, J. Wolf, B. Wasąg, W. Biernat, S. Finn, R. Kammler, Z. Tsourti, M. Rabaglio- Poretti, B. U. Ruepp, H. Roschitzki-Voser, R. A. Stahel, E. Felip, A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: The ETOP NICHE trial. Journal of Clinical Oncology 35, 9070-9070, 2017.
56. M. de Martino, D. Zhuang, T. Klatte, M. Rieken, M. Roupret, E. Xylinas, T. Clozel, M. Krzywinski, O. Elemento, S. F. Shariat, Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer Biol Ther 15, 1239-1247, 2014.
57. O. Metzger-Filho, EP Winer, I Krop, Pertuzumab: optimizing HER2 blockade. Clinical Cancer Research 19, 5552-5556, 2013.
58. PR Pohlmann, IA Mayer, R Mernaugh, Resistance to Trastuzumab in Breast Cancer. Clinical Cancer Research 15, 7479-7491, 2009.
59. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, Dimaio JM, Milchgrub S, Smith AL, Souza RF, Gilbey L, Zhang X, Gandia K, Vaughan MB, Wright WE, Gazdar AF, Shay JW, Minna JD, Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64, 9027-9034, 2004.
60. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS, Ramirez RD, Sunaga N, Gazdar AF, Shay JW, Minna JD, Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 66, 2116-2128, 2006.